Virbac (LTS:0NM7) Total Equity: €1,125 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0NM7 Virbac SA LTS:0NM7
91 GF Score
Price €325.75
GF Value €363.49
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Virbac Total Equity?

Virbac LTS:0NM7 +2.04% 91 Total Equity is €1,125 Mil as of Dec. 2025. GuruFocus rates LTS:0NM7 with a GF Score™ of 91/100 and a GF Value™ of €363.49 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Virbac's total equity for the quarter that ended in Dec. 2025 was €1,125 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Virbac Total Equity Historical Data

* Premium members only.

The historical data trend for Virbac's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Virbac Total Equity Chart

Virbac Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 725.19 839.29 909.92 1,043.40 1,124.98

Virbac Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 909.92 994.24 1,043.40 1,065.14 1,124.98
LTS:0NM7
91GF Score
Virbac SA LTS:0NM7
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Virbac Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Virbac's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1914.167-789.185
=1,125

Virbac's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=1914.167-789.185
=1,125

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €1,125 Mil mean?
Virbac (LTS:0NM7) has a Total Equity of €1,125 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Virbac and its competitors.
Is Virbac's Total Equity too high?
Virbac's current Total Equity is €1,125 Mil. Overall, Virbac has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Virbac's Total Equity compare to LLY and JNJ?
Virbac's Total Equity of €1,125 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Drug Manufacturers company?
A good Total Equity depends on the Drug Manufacturers industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Virbac and its competitors. Virbac's current Total Equity is €1,125 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virbac stock overvalued right now?
Based on GuruFocus' analysis, Virbac (LTS:0NM7) is currently considered Modestly Undervalued. The stock's GF Value™ is €363.49, compared to a current price of €325.75 — trading 10.4% below its estimated fair value. The current Total Equity is €1,125 Mil. Virbac's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Virbac (LTS:0NM7), the current Total Equity is €1,125 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Virbac (LTS:0NM7) Overvalued in 2026?

Based on GuruFocus' analysis, Virbac stock appears to be undervalued. The current stock price of €325.75 is trading 10.4% below its estimated GF Value™ of €363.49. GuruFocus considers Virbac to be Modestly Undervalued.

Key valuation signals for LTS:0NM7:

  • Total Equity: €1,125 Mil
  • GF Value™: €363.49 vs. price of €325.75 (10.4% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the LTS:0NM7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Virbac Business Description

Address 13e rue, 1ere avenue 2065, LID - BP 27, Carros, FRA, 06511
Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.
91GF Score

Get the complete analysis for LTS:0NM7

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€325.75
Price
€363.49
GF Value